Novo Nordisk Faces a Demand Flood as Production Race Nears Critical Juncture

A pair of catalysts is converging on Novo Nordisk just as the Danish drugmaker scrambles to expand its manufacturing footprint. On July 1, millions of US seniors will gain subsidised access to Wegovy through Medicare, paying only $50 a month in co-pays. Around ten percent of plan members meet the medical criteria, opening a vast new addressable market. Meanwhile, the oral version of Wegovy has racked up more than three million prescriptions in roughly five months, pulling in predominantly first-time users rather than cannibalising the injection.

The timing of these demand triggers is both a blessing and a pressure test. Novo Nordisk is racing to bring new factories online in the Czech Republic, Ireland and France to close the supply gap that has dogged its diabetes and obesity franchises. A facility in the Czech Republic began producing carrier proteins for next-generation medicines in June, while the Irish and French sites are slated to start manufacturing oral GLP-1 formulations by 2028. The company also launched the combination therapy Kyinsu in China in June.

Yet the production ramp has already hit a snag. The newly acquired filling plant in Bloomington, Indiana continues to wrestle with regulatory issues, and any delays to the broader expansion would prolong shortages and cede hard-won market share. Competitors such as Eli Lilly are pressing their advantage, and the field of oral GLP-1 candidates from rivals is thickening, putting pricing power under sustained pressure. The expiry of the original semaglutide patent only adds to the long-term erosion risk.

Management has already warned of a currency-adjusted sales decline of five to thirteen percent for 2026, alongside an operating profit drop of four to twelve percent. The shares reflect this caution: at around €41.85, they sit 32 percent below their 52-week high and have lost nearly 29 percent year-to-date. The Relative Strength Index has climbed to 70, flashing an overbought signal that tempers the recent rally from the March trough of roughly €31.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

To shore up confidence, Novo Nordisk is ploughing up to DKK 15 billion into a share buyback programme running until February 2027. It now holds nearly one percent of its own outstanding stock. The buyback provides a floor, but the bigger question is whether production can keep pace with demand without further stumbles.

The next major catalysts are sharply defined. On August 5, the company will report second-quarter earnings, and investors will scrutinise the retention rate of oral Wegovy users—a metric that determines the durability of that revenue stream. Later in the year, the FDA is expected to rule on CagriSema, a pipeline candidate that could reshape the obesity treatment landscape. A clean approval would add firepower to Novo Nordisk’s already formidable weight-loss franchise.

For now, the share price is caught between the promise of blockbuster demand and the reality of a factory-floor bottleneck. If the new plants come online without further regulatory or operational hiccups, the stock could regain momentum. If the supply headaches persist, the weak 2026 profit forecast will weigh even more heavily on the equity. All eyes are on the production numbers and the Medicare uptake data as the next test begins.